Atherosclerosis is an inflammatory process triggered by the presence of lipids in the vascular wall and encompasses a complex interaction between inflammatory cells, vascular elements and lipoproteins through the expression of several adhesion molecules and cytokines. Activation of the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) has been demonstrated to modulate many aspects of lipoprotein metabolism and inflammation in vitro as well as in animal and human studies. The tissue distribution of PPAR-α is extensive and it is abundantly present in the vascular wall where it may mediate many of anti-inflammatory and antiatherogenic effects. Major clinical trials, such as the Veterans Affairs High-Density Lipoprotein Intervention Trial, the Helsinki Heart Study and the Diabetes Atherosclerosis Intervention Study, have demonstrated the beneficial effects of synthetic agonists of PPAR-α, specifically fibric acid derivatives, on cardiovascular disease outcome. Although fibric acid trials have reported cardiovascular risk reduction in patients with dyslipidemia, the favorable alterations in plasma lipids can only partially explain the reduction in cardiovascular events in these studies. One common link among these trials was a cohort with a high prevalence of insulin resistance or diabetes, conditions associated with heightened systemic inflammation and increased risk for development and progression of atherosclerosis. In this paper, we will review the many antiatherogenic effects of PPAR-α ligands and evidence from fibric acid trials that individuals with insulin resistance or diabetes benefit the most from these drugs, consistent with their anti-inflammatory and antithrombotic properties.

Keywords:
Fibric acids, Peroxisome proliferator-activated receptor-α, Atherosclerosis, Cardiovascular disease, Inflammation
1.
Marx M, Libby P, Plutzky J: Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: Possible mediators of cardiovascular risk? J Cardiovasc Risk 2001;8:203–210.
2.
Neve B, Fruchart J, Staels B: Role of peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60:1245–1250.
3.
Ziouzenkova O, Perry S, Asatryan L, et al: Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003;100:2730–2735.
4.
Fruchart J, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3:83–92.
5.
Sun Z, Andersson R: NF-κB activation and inhibition: A review. Shock 2002;18:99–106.
6.
Karin M, Chang L: AP-1-glucocorticoid receptor crosstalk taken to higher level. J Endocrinol 2001;169:447–451.
7.
Adcock IM: Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 1997;52:178–186.
8.
Kleeman R, Gervois PP, Verschuren L, et al: Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood 2003;101:545–551.
9.
Blake G, Ridker P: Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763–771.
10.
Gervois P, Vu-Dac N, Kleeman R, et al: Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 2001;276:33471–33477.
11.
Staels B: The PPAR system and regulation of lipoprotein metabolism; in Betteridge (Editor): Lipids and Vascular Disease – Current Issues. Martin Dunitz, 2001, pp 27–37.
12.
Martin-Nizard F, Furman C, Delerive P, et al: Peroxisome proliferator-activated receptor activation inhibits oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Risk 2000;40:822–831.
13.
Plutzky J: Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001;12:511–518.
14.
Pasceri V, Chang J, Willerson JT, et al: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerotic drugs. Circulation 2001;103:2531–2534.
15.
Staels B, Koenig W, Habib A, et al: Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not PPAR-γ activators. Nature 1998;393:790–793.
16.
Neve BP, Corseaux D, Chinetti G, Zawadzki C, et al: PPAR-α agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001;103:207–219.
17.
Duez H, Fruchart J, Staels B: PPARs in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001;8:184–194.
18.
Marx N, Sukhova G, Collins T, et al: PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125–3131.
19.
Marx N, Kehrle B, Kohlhammer K, et al: PPAR activators as anti-inflammatory mediators in human T lymphocytes. Circ Res 2000;90:703–710.
20.
Rubins HB, Robins SJ, Collins D, et al: Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597–2604.
21.
Robins SJ, Rubins HB, Faas FH, et al: Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513–1517.
22.
Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779–1785.
23.
Steiner G, et al: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001;357:905–910.
24.
The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21–27.
25.
Ruotolo G, Ericsson CG, Tettamanti C, et al: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648–1656.
© 2005 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.